Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA1076
  • Published: 
Download guidance (PDF)

Advice

NICE is unable to make a recommendation about the use in the NHS of adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer in adults.

After the first committee meeting, the technology appraisal committee's preferred assumptions included using overall survival data from the KYRSTAL-12 trial in the economic model. Because this data is immature, Bristol Myers Squibb will consider restarting this evaluation when the final overall survival analysis can be included in the economic model.

Information

If NHS organisations wish to consider adagrasib for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7094-0